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Article

Higher CSF sTREM2 and microglia activation
are associated with slower rates of
beta-amyloid accumulation
Michael Ewers1,2,* , Gloria Biechele3, Marc Suárez-Calvet4,5,6 , Christian Sacher3, Tanja Blume2,
Estrella Morenas-Rodriguez7, Yuetiva Deming8 , Laura Piccio9,10,11, Carlos Cruchaga10,12,
Gernot Kleinberger7,13 , Leslie Shaw14, John Q Trojanowski15, Jochen Herms2 ,
Martin Dichgans1,2,16, the Alzheimer’s Disease Neuroimaging Initiative (ADNI)†, Matthias Brendel3,
Christian Haass2,7,16 & Nicolai Franzmeier1

Abstract
Microglia activation is the brain’s major immune response to
amyloid plaques in Alzheimer’s disease (AD). Both cerebrospinal
fluid (CSF) levels of soluble TREM2 (sTREM2), a biomarker of
microglia activation, and microglia PET are increased in AD;
however, whether an increase in these biomarkers is associated
with reduced amyloid-beta (Ab) accumulation remains unclear.
To address this question, we pursued a two-pronged translational approach. Firstly, in non-demented and demented individuals, we tested CSF sTREM2 at baseline to predict (i) amyloid
PET changes over  2 years and (ii) tau PET cross-sectionally
assessed in a subset of patients. We found higher CSF sTREM2
associated with attenuated amyloid PET increase and lower tau
PET. Secondly, in the AppNL-G-F mouse model of amyloidosis, we
studied baseline 18F-GE180 microglia PET and longitudinal
amyloid PET to test the microglia vs. Ab association, without any
confounding co-pathologies often present in AD patients. Higher
microglia PET at age 5 months was associated with a slower
amyloid PET increase between ages 5-to-10 months. In conclusion, higher microglia activation as determined by CSF sTREM2

or microglia PET shows protective effects on subsequent amyloid
accumulation.
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Introduction
The deposition of amyloid-b (Ab) peptide is a key primary alteration that defines Alzheimer’s disease (AD), involving a cascade
of pathological brain changes resulting in the occurrence of
dementia symptoms (Hardy & Higgins, 1992; Selkoe & Hardy,
2016). Recent evidence from genome-wide association studies
suggests that alterations in the innate immune system are associated with enhanced risk of AD and thus modulate the development of AD (Lambert et al, 2009; Guerreiro et al, 2013; Jonsson
et al, 2013; Reitz et al, 2013; Efthymiou & Goate, 2017; Sims
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et al, 2017; Jansen et al, 2019). Microglia activation is the
brain’s major innate immune response to pathogens, and reactive microglia surrounding the amyloid plaques are a hallmark
of AD (Itagaki et al, 1989). Microglia activation involves the
phagocytosis of amyloid plaques as well as a reduction in Abneurotoxicity and thus plays a key role to restore brain homeostasis (Sarlus & Heneka, 2017; Butovsky & Weiner, 2018).
However, microglia activation can also be detrimental by inducing neurotoxic inflammation (Meda et al, 1995; Hong et al,
2016). Hence, understanding the role of microglia activation in
response to core AD pathology (including Ab) is pivotal for both
tracking disease progression and identifying potential therapeutic
interventions.
The overall aim of our study was to assess whether microglial
function is associated with lower rates of Ab accumulation throughout the Alzheimer’s continuum. We addressed this question using
two different approaches. First, in humans, we tested whether cerebrospinal fluid levels of triggering receptor expressed on myeloid
cell type 2 (TREM2) as a marker of TREM2-mediated microglia
response predict a change in accumulation of Ab pathology. Second,
we tested in a mouse model of amyloidosis whether changes in GE
180 (i.e., a PET tracer of microglial activation) predict longitudinal
changes in Ab deposition.
Our study on TREM2 was motivated by previous findings in both
humans and animal models of Ab, suggesting that TREM2-related
microglia activation may have a protective role in AD (for review,
see Butovsky & Weiner, 2018). TREM2 is a transmembrane protein
of the immunoglobulin family that is expressed by immune cells
throughout the body, but in the brain almost exclusively by microglia (Hickman et al, 2013). TREM2 forms a signaling complex with
the DNAX activation protein 12 (DAP12) that triggers microglial
activation, associated with increased microglial proliferation,
chemotaxis, and phagocytosis of Ab fibrils, as well as reduction of
excessive pro-inflammatory responses (Takahashi et al, 2005; Wang
et al, 2015; Zhong et al, 2015; Keren-Shaul et al, 2017; Mazaheri
et al, 2017; Zhao et al, 2018). Genetic studies in humans showed
that rare variants in the TREM2 gene are associated with an exceptionally increased risk of AD, comparable to increase in risk by the
APOE e4 genotype (Guerreiro & Hardy, 2013; Jonsson et al, 2013),
suggesting that TREM2-related microglia activation may reduce the
risk of AD dementia.
The soluble TREM2 (sTREM2) fraction is detectable in the cerebrospinal fluid (CSF) (Piccio et al, 2008), possibly through a
mechanism of proteolytic cleavage of TREM2 and release into
interstitial fluid (Kleinberger et al, 2014; Schlepckow et al, 2017).
CSF sTREM2 is increased in humans with a biomarker profile of
AD years before the onset of dementia symptoms (Heslegrave
et al, 2016; Piccio et al, 2016; Suarez-Calvet et al, 2016a,b, 2019),
where higher CSF sTREM2 at a given biomarker level of Ab and
pathologic tau was associated with larger gray matter volume
(Gispert et al, 2016b) and slower subsequent cognitive and clinical decline in symptomatic elderly participants (Ewers et al,
2019). Together, these findings support a protective role of
elevated sTREM2 in AD in the symptomatic phase of AD.
However, whether increased CSF sTREM2 is associated with
reduced rates of longitudinal increase of fibrillar Ab is unclear.
Therefore, in the first part of our study we set out to determine
whether in elderly participants throughout the AD continuum,
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CSF sTREM2 levels at baseline are associated with longitudinal
changes in amyloid PET. In patients with AD, the rate of amyloid
PET accumulation does not increase in a linear fashion, but shows
a peak at about intermediate levels of global amyloid deposition
before leveling off again, thus resembling a quadratic curve across
the range of Ab brain levels (Villemagne et al, 2013). Here, we
hypothesized that higher CSF sTREM2 levels modulate this
dynamic change in the rate of amyloid PET increase, i.e., higher
CSF sTREM2 is associated with slower amyloid PET increase
during the peak phase of amyloid deposition. A secondary goal in
the current human PET study was to assess whether higher CSF
sTREM2 levels are associated with lower tau PET independent of
Ab levels. Recent studies on mouse models of tau pathology
suggest that that TREM2 deficiency is associated with higher tau
pathology (Jiang et al, 2015, 2016), although inconsistent findings
have been reported as well (Leyns et al, 2017). However, no study
in humans has yet tested whether higher CSF sTREM2 is associated with lower tau PET in elderly subjects with biomarker
evidence of Ab.
In the last part of our study, we assessed microglia PET as a
predictor of amyloid PET accumulation in a mouse model of
genetically caused Ab pathology. The use of mouse models of Ab
has the major advantage to assess any association between higher
microglia activation and lower Ab accumulation in a more
controlled setting, i.e., in the absence of potentially confounding
co-pathologies such as vascular changes that may drive microglia
activation in patients with AD, where mixed pathologies are
frequent (Kapasi et al, 2017). Furthermore, although CSF sTREM2
levels may reflect the amount of signaling-competent TREM2 on
the surface of microglia (Kleinberger et al, 2014; Schlepckow
et al, 2017) and thus provide a marker of microglia activation,
the link between CSF sTREM2 and microglia activation is not
firmly established. Therefore, we tested in mice the translocator
protein-18 kDa (TSPO) PET as a marker of microglia activation in
our second part of the study, reasoning that neuroimaging
approaches including TSPO-PET allow for a more direct in vivo
assessment of activated microglia activation in a longitudinal
fashion (Edison et al, 2018). In longitudinal dual tracer studies,
we previously showed that both microglia PET and amyloid PET
are increased in an age-dependent manner in mouse models of
amyloidosis (Brendel et al, 2017; Blume et al, 2018). Levels of
sTREM2 in brain homogenate were associated with higher microglia PET in mouse models for amyloid pathology, which was positively correlated with higher immunohistochemically determined
microglia numbers (Sacher et al, 2019), suggesting that higher
microglia PET in mice with amyloidosis reflects higher microglia
activation that is strongly correlated with TREM2 levels. We used
this dual tracer paradigm in transgenic mice to test whether
sporadically occurring interindividual variation in microglia activation at baseline is predictive of the rate of subsequent Ab deposition. Specifically, we obtained both 18F GE-180 TSPO microglia
PET and 18F-florbetaben amyloid PET in the AppNL-G-F mice,
which show global Ab deposition at 4 months of age (Saito et al,
2014), reaching a plateau by 9 months of age (Mehla et al, 2019).
We hypothesized that higher baseline microglia PET levels
assessed at 5 months of age are associated with slower rates of
amyloid PET increase during the subsequent follow-up period
until 10 months of age.
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Results
Patient characteristics
The baseline characteristics of all study participants are displayed in
Table 1. The overall sample included 300 participants (136 female)
with a mean (SD) age of 72.54 (6.4). The total sample included 94
CN Ab vs. 206 participants covering the Alzheimer’s continuum
(i.e., 55 CN Ab+, 136 MCI Ab+, 15 AD dementia). The sample size
of subject in the AD continuum was sufficient to detect an effect size
of R2 = 0.038 for our hypothesized effect of the interaction CSF
sTREM2 × AV45 PET on the rate of AV45 PET change at a power of
0.8 and alpha = 0.05. Compared to the CN Ab group, the Alzheimer’s continuum group showed abnormal AD biomarker levels (i.e.,
AV45 global SUVR, CSF total tau, CSF p-tau181) and cognition
(ADNI-MEM, MMSE), and these abnormalities increased in symptomatic stages (i.e., MCI Ab+, AD dementia). All group differences
were assessed at the pre-defined alpha level of 0.05 (two-tailed).
Inverse U-shaped association between baseline amyloid PET
levels and annual amyloid accumulation
Previous studies in autosomal dominant and sporadic AD have
shown that the rate of amyloid accumulation across the Alzheimer’s
continuum shows an inverse u-shape, where amyloid PET accelerates until a plateau is reached, after which amyloid PET accumulation decelerates (Villemagne et al, 2013; Gordon et al, 2018; Leal
et al, 2018). To confirm this inversely u-shaped amyloid PET accumulation in the current sample, we assessed association between
baseline AV45 PET levels and annual AV45 PET changes across the
pooled sample (i.e., CN Ab & Alzheimer’s continuum). Using a
linear mixed effects model, we confirmed in our sample the hypothesized inversely u-shaped (i.e., quadratic) effect of baseline AV45
PET on annual AV45 PET change (t(396) = 4.605, b/SE = 0.195/
0.042, 95% CI = [ 0.277; 0.113], P < 0.001, Cohen’s d = 0.463,
Fig 1A). Specifically, very low and very high baseline AV45 PET
levels were associated with little annual AV45 PET changes,
whereas intermediate AV45 PET levels were associated with relatively strong annual AV45 PET increases (controlling for baseline
age, gender, education, diagnosis, CSF p-tau181, APOE e4, time
between AV45 PET visits, and random intercept). The quadratic
model of baseline AV45 PET on annual AV45 PET showed a better
fit than the lineal model (v2(1) = 21.23, P < 0.001). Testing the
above described model in the Alzheimer’s continuum group only (t
(271) = 3.354, b/SE = 0.253/0.076, 95% CI = [ 0.399; 0.011],
P < 0.001, Cohen’s d = 0.407) and in symptomatic AD only (i.e.,
MCI and AD dementia, t(226) = 2.240, b/SE = 0.185/0.083, 95%
CI = [ 0.344; 0.026], P = 0.026, Cohen’s d = 0.298) yielded
consistent results. This finding confirms previous evidence that
annual AV45 PET increase (reflecting amyloid accumulation) accelerates initially but saturates at high AV45 PET levels. Results are
summarized in Table 2, and all reported P-values are two-tailed.
Higher CSF sTREM2 is associated with reduced amyloid
PET accumulation
We next tested our major hypothesis that elevated CSF sTREM2
levels are associated with slower amyloid accumulation (i.e., an
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attenuated u-shaped association between baseline amyloid and
amyloid accumulation). To this end, we tested whether CSF
sTREM2 (i) had a main effect on annual AV45 PET changes or (ii)
moderated the quadratic association between baseline AV45 PET
levels and annual AV45 PET changes. We tested this using linear
mixed effects models, controlling for baseline age, gender, education, diagnosis, CSF p-tau181, APOE e4, time between AV45 PET
visits, and random intercept.
We found a significant main effect of CSF sTREM2 on annual
AV45 PET change, such that individuals with higher CSF sTREM2
showed slower amyloid accumulation (t(395) = 2.584, b/
SE = 0.002/0.009, 95% CI = [ 0.0041;
0.0005]. P = 0.010,
Cohen’s d = 0.260). We further found a significant quadratic
interaction CSF sTREM2 × baseline AV45 on annual AV45 changes,
such that participants with higher CSF sTREM2 showed slower
acceleration of AV45 PET increase than participants with low
CSF sTREM2 levels (t(342) = 2.460, b/SE = 0.211/0.086, 95%
CI = [0.045; 0.376], P = 0.014, Cohen’s d = 0.266, Fig 1B). Comparing the first model including the CSF sTREM2 main effect vs. the
second model including the AV45 PET × CSF sTREM2 interaction
revealed better model fit for the interaction model (v2(2) = 8.426,
P = 0.015). When testing this interaction model in the Alzheimer’s
continuum group only (with abnormally high AV45 PET baseline
values), the interaction baseline AV45 PET × CSF sTREM2 on
annual AV45 PET changes was pronounced (t(268) = 3.861, b/
SE = 0.636/0.165, 95% CI = [0.320; 0.952], P < 0.001, Cohen’s
d = 0.472). Consistent effects were found when further restricting
the sample to symptomatic AD only, i.e., MCI Ab+ & AD dementia
(t(225) = 3.225, b/SE = 0.601/0.186, 95% CI = [0.245; 0.957],
P = 0.001, Cohen’s d = 0.432). Results are summarized in Table 2,
and reported P-values are two-tailed. In order to determine stages
of amyloidosis in which beneficial sTREM2 effects on subsequent
amyloid accumulation are largest, we performed sliding window
analyses (n = 100 per window shifted in steps of 10) across low to
high baseline AV45 levels. In each window, we assessed standardized group differences (i.e., Cohen’s d) in subsequent AV45 change
between subjects with high and low sTREM2 levels (i.e., defined
via median split within each window). When plotting the resulting
sTREM2-related differences in AV45 change, we found that beneficial effects of sTREM2 on future amyloid accumulation (i.e., positive Cohen’s d values) were highest (Cohen’s d ~ 0.2–0.4) in
windows around baseline AV45 SUVRs between 0.9–1.0, where
annual AV45 change peaks (i.e., at baseline AV45 PET = 0.95, see
Fig EV1). Together, these findings suggest that participants with
higher CSF sTREM2 show slower amyloid accumulation than participants with lower CSF sTREM2.
Higher GE-180 PET is associated with slower amyloid PET
increase in an AD mouse model
We next tested whether the association between higher microglial
activation and slower amyloid accumulation could be confirmed in a
mouse model of amyloidosis. To this end, we assessed longitudinal
Florbetaben PET (as a marker of Ab accumulation) and GE-180 PET
(as a marker of microglia activation) in transgenic AppNL-G-F mice.
First, we verified that the AppNL-G-F exhibited the expected increase
in Florbetaben PET and GE-180 PET at baseline and over time when
compared to that in the wild-type mice. Regression analyses showed
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Table 1. Baseline sample characteristics.
Controls

AD spectrum

CN Ab
N = 94

CN Ab+
N = 55

MCI Ab+
N = 136

AD dementia
N = 15

P-value

Age

72.9 (5.88)

72.9 (6.00)

Gender (f/m)

41/53

34/21c

Education

16.9 (2.37)

16.2 (2.67)

16.2 (2.61)

15.5 (2.70)

ApoE4 (pos/neg)

81/13b,c,d

30/25a,d

51/85a

2/13a,b

ADNI-MEM

1.18 (0.56)c,d

1.17 (0.68)c,d

0.18 (0.61)a,b,d

MMSE

29.2 (1.07)

29.1 (0.88)

27.8 (1.81)

22.5 (1.81)a,b,c

< 0.001
< 0.001

d

c,d

d

c,d

71.6 (6.54)

77.9 (7.22)

0.003

56/80b

5/10

0.047

d

a,b,d

a,b,c

0.83 (0.33)a,b,c

0.099
< 0.001
< 0.001

AV45 global SUVR

0.74 (0.03)

0.91 (0.10)

0.97 (0.11)

1.05 (0.07)

Time between AV45 visits

2.16 (0.59)b,c,d

2.33 (0.85)a,c,d

2.12 (0.50)a,b,d

2.00 (0.03)a,b,c

CSF sTREM2

4,163 (2,086)

3,701 (2,007)

4,317 (2,212)

4,640 (2,599)

CSF total tau

220 (78.3)c,d

268 (107)c,d

333 (132)a,b

381 (118)a,b

< 0.001

19.3 (7.11)b,c,d

25.8 (11.4)a,c,d

32.9 (14.4)a,b

39.1 (12.9)a,b

< 0.001

14

14

26

0

CSF p-tau181
e

Number of participants with tau PET

0.098
0.270

Sig. (P < 0.05) different from CN AB .
b
Sig. (P < 0.05) different from CN AB+.
c
Sig. (P < 0.05) different from MCI AB+.
d
Sig. (P < 0.05) different from AD dementia.
e
Tau PET had to be obtained maximum 3 years after the last joint AV45 PET/CSF sTREM2 assessment.
a

that at baseline (5 months), GE-180 PET (t(56) = 8.369, P < 0.001,
Fig 2A) and Florbetaben PET (t(56) = 2.652, P = 0.010) were higher
in AppNL-G-F compared to age- and gender-matched C57BL/6 control
mice, suggesting both amyloidosis and microglial activation in the AD
mouse model. When assessing the rate of increase in Florbetaben PET
at from 5 to 10 months of age, AppNL-G-F mice also showed faster
increase in Florbetaben PET compared to C57BL/6 control mice (t
(56) = 5.551, P < 0.001, Fig 2B).
Next, we tested our main hypothesis, i.e., whether higher baseline GE-180 PET (assessed at 5 months) predicts slower rate of Florbetaben PET up to 10 months of age. Using linear regression, we
found that higher baseline GE-180 PET levels (continuous measure)
predicted slower longitudinal increase in Florbetaben PET in the
AppNL-G-F mice, controlling for baseline Florbetaben PET (t
(12) = 2.354, b/SE = 0.367/0.198, P = 0.036, Fig 2C). Figure 3
illustrates the GE-180 and Florbetaben uptake in the C57BL/6
control mice (Fig 3A) and the AppNL-G-F split into subgroups of low
(Fig 3B) and high (Fig 3C) baseline GE-180 PET. Note that continuous rather than binarized GE 180 PET levels were included as a
predictors in the regression analysis described above to avoid any
potential bias. Visual inspection of the figure shows that AppNL-G-F
mice with high baseline microglia activity showed a reduced
increase in amyloid PET uptake during the ensuing 5 months of
follow-up compared to those AppNL-G-F mice who showed low GE180 PET at baseline, confirming that higher GE 180 PET at baseline
is associated with reduced subsequent increase in Florbetaben PET.
Higher sTREM2 is associated with lower tau PET independent
of amyloid
In a last step, we tested whether higher sTREM2 levels are associated with lower tau PET uptake. Since tau PET was only introduced
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recently in ADNI3, all CSF sTREM2 measures were obtained prior to
tau PET assessments. For the current analyses, we selected only 54
subjects for which tau PET was acquired maximum 3 years after a
joint CSF sTREM2 & AV45 assessment (i.e., 14 CN Ab , 14 CN Ab+,
26 MCI Ab+). The mean time difference between CSF sTREM2/
AV45 and tau PET assessment was 1.6  1.12 years. Using
ANCOVAs, we found that subjects with higher sTREM2 levels
showed lower tau PET SUVR in Braak-stage 1 ROIs (i.e., entorhinal
cortex; F7,46 = 9.527, P = 0.005) & Braak-stage 3&4 ROIs
(F7,46 = 5.253, P = 0.032), controlling for age, gender, education,
diagnosis, ApoE4 status, and AV45. No significant effects of CSF
sTREM2 were found, however, on tau PET SUVR in Braak-stage 5&6
ROIs (F7,46 = 2.810, P = 0.108). Results are summarized in Fig 4.
When applying a Bonferroni-corrected alpha threshold of 0.0167,
the effect of CSF sTREM2 on tau PET SUVR in Braak-stage 1 (i.e.,
entorhinal cortex) remained significant.

Discussion
The primary finding of the current study was that higher CSF
sTREM2 levels at baseline were associated with slower rates of Ab
accumulation as assessed by amyloid PET over 2 years in elderly
participants, supporting a protective role of higher CSF sTREM2 in
the development of amyloid pathology. Secondary analysis of the
CSF sTREM2 effects on AV1451 tau PET showed that higher CSF
sTREM2 was associated with lower tau PET uptake in early Braakstage regions, supporting a protective role of TREM2 in the development of key AD pathology. The second major finding was that in a
transgenic mouse model of Ab pathology, higher microglia PET
signal at baseline was associated with slower rate of amyloid PET
increase. These results are supportive of our findings in humans.
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Annual AV45 change (z−score)

A
2

0

−2

−4

Quadratic main effect
AV45 SUVR
b/se = -0.195/0.042
95% CI = [-0.277;-0.113]
p = 0.0000078

0.8

1.0

1.2

AV45 SUVR

B

CSF sTREM2

Annual AV45 change (z−score)

<median
>median
2

0

−2

−4

Quadratic interaction
sTREM2 x AV45 SUVR
b/se = 0.211/0.086
95% CI = [0.045/0.376]
p = 0.014

0.8

1.0

1.2

AV45 SUVR

Figure 1. Association between baseline amyloid and amyloid PET
change.
A, B Regression plot showing the association between baseline AV45 PET
(x-axis) and annual AV45 PET change (y-axis) across the entire sample
(N = 300). The vertical dashed line represents the Ab-positivity threshold
of AV45 PET SUVR > 0.079 (A). Regression plot for the association
between baseline AV45 PET and annual AV45 PET change stratified by
baseline CSF sTREM2 levels (B).
Source data are available online for this figure.

Although the current observational study does not purvey a causative effect of sTREM2 or microglia activation on Ab accumulation,
our results support the view that microglia activation during intermediate levels of Ab is associated with less strong Ab accumulation.
Consistent with previous studies (Villemagne et al, 2013; Gordon
et al, 2018; Leal et al, 2018), we found that the rate of Ab accumulation follows a quadratic function across baseline Ab levels, i.e., the
increase accelerates until an intermediate level of Ab deposition
before gradually slowing down again. Importantly, we found that
higher levels of CSF sTREM2 alter this dynamic change in Ab,
reducing the rate of increase in amyloid PET during the phase of the
strongest increase in Ab. Thus, we demonstrate here that CSF
sTREM2 modulates the accumulation of a key AD pathology,
extending previous reports of higher CSF sTREM2 (Gispert et al,
2016b; Ewers et al, 2019) and higher microglia PET (Hamelin et al,
2016) to be associated with lower brain atrophy and slower cognitive decline in patients with AD. Furthermore, a common genetic
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variant in the 4-domain subfamily gene MS4A4A that is associated
with decreased risk of AD was found to be associated with higher
CSF sTREM2 levels (Deming et al, 2019), suggesting that higher
sTREM2 levels may contribute to a decreased risk of AD. The
current findings are also broadly consistent with a previous brain
autopsy study reporting that individuals carrying TREM2 mutations
exhibit lower amyloid plaque-associated microglia activation, less
microglial clustering (Parhizkar et al, 2019), and higher neuritic
plaque score (Prokop et al, 2019). Neuritic plaques are the most
important source for amyloid PET binding (Clark et al, 2012; Ikonomovic et al, 2016), and thus, the current findings of higher CSF
sTREM2 to be associated with lower amyloid PET binding are
consistent with the post-mortem findings of TREM2 risk variants
and increased neuritic plaque score.
Our observation of higher CSF sTREM2 and lower amyloid PET
is further supported by results from transgenic mouse models,
where a number of studies suggest a protective effect of TREM2related microglia activation on Ab (Yuan et al, 2016; Parhizkar et al,
2019; for review, see Butovsky & Weiner, 2018). In 5×FAD mice
which show Ab deposition in the hippocampus and cortex by
6 months of age (Oakley et al, 2006), knockdown of the TREM2
gene decreased microglia activation but increased amyloid plaque
load at ages 8 months in the hippocampus (Wang et al, 2015) and
cortex (Griciuc et al, 2019). In contrast, overexpression of the
TREM2 gene induced lower amyloid plaque load at 7 months (Lee
et al, 2018). In APP-PS1 mice, which show widespread amyloid
plaques in the brain by 3–4 months of age (Radde et al, 2006),
TREM2 knockdown was associated with higher amyloid plaque
burden at 8 months (Jay et al, 2017) and 12 months (Sheng et al,
2019), i.e., when amyloid plaque deposition is already quite
expanded but still increasing. TREM2 knockout in the APPPS1 mice
was associated with increased Ab seeding induced amyloid plaque
burden at 6 months of age (Parhizkar et al, 2019). Together, these
results suggest a protective effect of TREM2 on the accumulation of
Ab during a phase of intermediate levels of Ab, i.e., when Ab accumulation is still increasing over time. This observation in the transgenic mice is consistent with our results of CSF sTREM2 to
modulate the increase in Ab accumulation particularly during intermediate levels of Ab (as shown by the interaction between sTREM2
and the quadratic term of AV45 PET). This stance is consistent with
the proposal that any TREM2-dependent beneficial effects on
amyloid are stage-dependent and occur preferentially at later stages
of Ab (Jay et al, 2017), which may explain why some studies did
not find a beneficial effect of TREM2 on Ab (Jay et al, 2015; Krasemann et al, 2017).
In addition to an association between higher CSF sTREM2 and
lower rates of amyloid deposition, we found in a secondary analysis
that higher CSF sTREM2 was associated with lower cross-sectionally
assessed levels of AV1451 tau PET, especially in early Braak-stage
ROIs. The time delay between CSF sTREM2 and the single AV1451
PET did not permit to test whether the effect of CSF sTREM2 on
AV1451 PET was mediated by lower rates of amyloid PET. Interestingly, a recent study in a transgenic mouse model of Ab reported
that genetically induced TREM2 deficiency was associated with
higher pathologic tau seeding in neurotic plaques (Leyns et al,
2019). These results correspond well to post-mortem histochemical
findings of higher tau burden in the microevironment of amyloid
plaques in AD patients with the TREM2 mutations (Prokop et al,
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Table 2. Linear mixed models testing the effects of baseline AV45 and CSF sTREM2 on annual AV45 PET change.
Dependent variable: annual AV45 change

b/SE

95% CI

Partial R2

t-value

P-value

Cohen’s d

4.605

< 0.001

0.463

0.050

2.584

0.010

0.260

0.016

2.460

0.014

0.266

0.015

3.354

< 0.001

0.407

0.039

2.400

0.017

0.292

0.020

3.861

< 0.001

0.472

0.051

2.240

0.026

0.298

0.021

2.563

0.011

0.342

0.027

3.225

0.001

0.432

0.042

Whole group
Model 1a: Main effect—Baseline AV45 SUVR2

0.195/0.042

0.277;

0.113

Model 2 : Main effect—Baseline CSF sTREM2

0.023/0.009

0.0041;

Model 3b: Interaction—Baseline AV45 SUVR2 × CSF sTREM2

0.211/0.086

0.045; 0.376

b

0.0006

AD continuum
Model 1a: Main effect—Baseline AV45 SUVR2

0.253/0.076

0.399;

0.011

Model 2 : Main effect—Baseline CSF sTREM2

0.003/0.001

0.0053;

Model 3b: Interaction—Baseline AV45 SUVR2 × CSF sTREM2

0.636/0.165

0.320; 0.952

b

AD clinical (MCI Ab+ & AD Dementia)

0.0006

a

Model 1a: Main effect—Baseline AV45 SUVR2

0.185/0.083

Model 2 : Main effect—Baseline CSF sTREM2

0.004/0.001

Model 3b: Interaction—Baseline AV45 SUVR2 × CSF sTREM2

0.601/0.186

b

0.344;

0.026

0.0062; 0.0009
0.245; 0.957

AD preclinical (CN Ab+)
Model 1c: Main effect—Baseline AV45 SUVR2

0.718/0.176

1.043;

4.092

< 0.001

1.047

0.197

Model 2d: Main effect—Baseline CSF sTREM2

0.002/0.002

0.006; 0.002

0.802

0.426

0.207

0.009

Model 3d: Interaction—Baseline AV45 SUVR2 × CSF sTREM2

0.214/0.364

0.872; 0.443

0.589

0.558

0.155

0.005

0.392

a

Model controlled for age, gender, education, diagnosis, CSF p-tau181, ApoE4 status, time between AV45 visits, and random intercept.
b
Model controlled for AV45 SUVR2, age, gender, education, diagnosis, CSF p-tau181, ApoE4 status, time between AV45 visits, and random intercept.
c
Model controlled for age, gender, education, CSF p-tau181, ApoE4 status, time between AV45 visits, and random intercept.
d
Model controlled for AV45 SUVR2, age, gender, education, CSF p-tau181, ApoE4 status, time between AV45 visits, and random intercept.
All P-values are based on two-tailed alpha thresholds.

2019). These results suggest the possibility that TREM2 plays an
important role in Ab-related tau pathology, which could potentially
underlie the CSF-TREM2-associated decrease in neurofibrillary
tangle deposition observed in the current study. However, whether
a direct mechanistic link between TREM2 function and neurofibrillary tangles exists remains to be investigated.
For the association between higher CSF sTREM2 and lower
amyloid PET accumulation, several potential mechanisms may
account for the observed results. Causal gene expression network
analysis showed the TREM2/DAP12 complex as a key regulator hub
for microglia gene expression in AD (Zhang et al, 2013; Wang et al,
2015; Keren-Shaul et al, 2017; Parhizkar et al, 2019). TREM2 activation increases the ApoE-dependent phenotypic switch from a homeostatic to a disease-associated microglial signature in response to Ab
(Krasemann et al, 2017; Parhizkar et al, 2019). Furthermore,
TREM2 deficiency causes reduced proliferation (Kleinberger et al,
2017; Zhao et al, 2018) and chemotaxis of microglia (Mazaheri
et al, 2017), resulting in reduced number of microglia around
amyloid plaques and phagocytosis of Ab (Zhao et al, 2018;
Parhizkar et al, 2019). Thus, TREM2 may be key to microglia activation with beneficial effects on Ab pathology.
Our findings in the transgenic mouse model of Ab pathology
demonstrating higher microglia PET at baseline to be associated
with slower amyloid PET accrual are also consistent with the idea of
a protective role of microglia activation. Our results are in general
agreement with previous reports of experimentally increased
TREM2 to be associated with lower Ab deposition (Lee et al, 2018),
and genetically induced TREM2 deficiency to be associated with
higher Ab deposition at a time window of advanced but still accumulating Ab in transgenic mouse models of Ab (Jay et al, 2017;
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Sheng et al, 2019). Importantly, our results suggest that lower
amyloid rates were associated with higher sporadically occurring
microglia activity, rather than as a consequence of microglia activation manipulated by genetic mutations, which in humans only
rarely occurs in carriers of TREM2 risk variants. Our findings
provide thus an important advance because microglia alterations,
such as those induced by loss-of-function TREM2 risk variants,
may not necessarily be translatable to the effects of increased
microglia activation in disease. Our findings on beneficial associations of microglia PET with subsequent Ab during a phase of
advanced yet still increasing Ab in the mouse model of Ab show
parallels to our findings on higher CSF sTREM2 to be associated
with lower subsequent amyloid PET increase in elderly individuals, in particular during a phase of intermediate Ab deposition at
baseline. The results are also consistent with previous findings on
[18F] DPA-714 TSPO-PET, a marker of microglia activation, in
patients with prodromal AD and AD dementia, where higher levels
of baseline microglia PET showed protective effects on the clinical
progression (Hamelin et al, 2016, 2018). Overall, these results
support that higher microglia activation modulates the accumulation of Ab in both mice and humans, and can obtain a protective
role.
The mechanisms underlying differences in microglia activation at
the same level of pathology are unclear. One possible source is that
microglia activation may differ as a function of different amyloid
plaque morphologies (Griffin et al, 1995). Microglia activation is
most strongly linked to neuritic rather than diffuse plaques (Sheng
et al, 1997). Thus, it is possible that mice with higher GE 180 PET at
baseline had more mature neuritic plaques and thus advanced levels
of amyloid deposition, entailing a ceiling effect. However, it is
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Figure 2. Rate of change in Florbetaben PET vs. baseline GE180 PET.
A, B Boxplots (central band = median, boxes = quartiles, whiskers = 1.5 *
interquartile range), illustrating the differences in GE180 PET (A) and the
rate of change in Florbetaben PET (B) compared between wild-type
C57BL/6 mice (n = 43) and APPNL-G-G (n = 15).
C
The regression plot shows lower rate of change in Florbetaben PET to be
associated with lower GE180 PET at baseline, i.e., at 5 months of age (C).
The shaded area corresponds to the 95% CI of the regression line.

Figure 3. Brain rendering of GE180 and Florbetaben PET by group and
time point.
A–C Coronal (top row) and axial (bottom row) slices of average 18-F GE-180
TSPO (microglia) tracer and 18F-florbetaben amyloid PET split up by
group (A–C): C57BL/6 (A), APPNL-G-F mice subgroup with a low (< median)
GE-180 PET (B), and the APPNL-G-F mice subgroup with a high (> median)
GE-180 PET (C). APPNL-G-F mice with low baseline GE180 PET levels
showed faster increase in Florbetaben PET between 5 and 10 months (B)
compared to those at high baseline level of GE-180 PET (C).

Source data are available online for this figure.

unlikely that ceiling effects of amyloid deposition explain the
current results, because in agreement with previous studies (Mehla
et al, 2019), the AppNL-G-F mice in the current study showed
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substantial increase in Florbetaben PET between 5 and 10 months
of age. Another possibility is that other less controllable interindividual differences in behavior such as physical activity and exploratory behavior may have modulated microglia activity in the
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p = 0.032

p = 0.108

AV1451 SUVR
(log−transformed z−score)

4

sTREM2

2

a

<median

a

>median

0

−2
Braak 1

Braak 3&4

Braak 5&6

Figure 4. TREM2 vs. tau PET.
Effects of sTREM2 on AV1451-PET-assessed tau pathology stratified by Braak
stages shown as boxplots (central band = median, boxes = quartiles,
whiskers = 1.5 * interquartile range).
Source data are available online for this figure.

transgenic mice. A number of previous studies that systematically
stimulated physical activity and exploratory behavior by enriched
environment showed a reduction in the accumulation of soluble Ab
and amyloid plaque burden in transgenic mouse models of Ab
(Moore et al, 2016; Zhang et al, 2018), possibly mediated by
enhanced microglial phagocytotic activity and thus Ab deposition
(Ziegler-Waldkirch et al, 2018). However, we did not investigate
systematically physical or exploratory activities in the mice, and
thus, the sources of sporadic differences in microglia activation at
the same level of Ab remain to be clarified in future studies.
Some caveats need to be taken into account for the interpretation
of the current findings.
In humans, we assessed CSF levels of sTREM2 rather than the
actual TREM2 or microglia activation in the brain. However,
several lines of evidence support the notion that sTREM2 probably
reflects the amount of signaling-competent TREM2 on the surface
of activated microglia and can be thus used as a surrogate marker
of TREM2-mediated microglia response: First, the levels of
sTREM2 in the brain of an Ab mouse model correlate with TSPOPET signal (Brendel et al, 2017). Second, mouse models bearing
the TREM2 p.T66M mutation show decreased microglial activity
(Kleinberger et al, 2017). Lastly, individuals with TREM2 risk
variants have reduced post-mortem levels of microglia surrounding amyloid plaques (Prokop et al, 2019), and CSF sTREM2 levels
are altered in TREM2 risk variants in vivo (Suarez-Calvet et al,
2019).
Another caveat is that measuring CSF sTREM2 does not allow
us to differentiate between the effect of TREM2 or a potential
unique role of its soluble form. Injection of sTREM2 into the
brains of transgenic mice with Ab deposition reduced amyloid
plaque load in a microglia-mediated way (Zhong et al, 2019),
suggesting that sTREM2 may exert a functional role in reducing
Ab rather than being an inert cleavage product. Still, several
observations suggest that the current findings are unlikely to be
reduced to direct effects of sTREM2 on Ab. As mentioned above,
sTREM2 in brain homogenate was associated with higher
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microglia PET suggesting that sTREM2 varies as a function of
microglia activity and TREM2 loss-of-function homozygous mutations are associated with dramatically decreased levels of
sTREM2. Together, these results suggest that higher sTREM2
levels are associated with higher microglia activation. Still, we
acknowledge that the association between CSF sTREM2 levels and
microglia activation remains to be established in humans. Another
caveat is that the current study is correlational in nature and does
not test microglia activation as a causal event. However, our stepwise effect size analysis showed that the size of the association
between high CSF sTREM2 and rate of amyloid PET change was
highest around the peak rate of AV45 PET accumulation, speaking
against the alternative hypothesis that high levels of CSF sTREM2
simply coincide with low amyloid accumulation during the course
of AD. Still, it is important to note that the current study does not
necessarily imply that microglia activation causes lower amyloid
accumulation, rather we demonstrate that CSF sTREM2 levels and
microglia PET are predictive of lower future amyloid PET accumulation. Furthermore, microglia activation and neuroinflammation in
AD are complex and heterogenous involving multiple pathways
(e.g., IL6, IL-1b, and YKL-40) and several studies suggest that
microglia activation can have adverse effects in AD (Llorens et al,
2017; Kinney et al, 2018; Gotzl et al, 2019; for review, see
Butovsky & Weiner, 2018). For example, CSF levels of YKL-40
have been previously reported to be increased in Alzheimer’s
disease, peaking at the prodromal stage (Gispert et al, 2016a), similarly to what has been described for CSF sTREM2 (Suarez-Calvet
et al, 2016b). It remains to be investigated whether YKL-40 regulates the rate of amyloid pathology, which we could not address in
the current study. The current study is limited with regard to range
of AD disease severity, but effects of microglia activation may vary
by disease stage as suggested by results from transgenic mice (Jay
et al, 2017; Parhizkar et al, 2019; Meilandt et al, 2020) and clinical
trials in humans (Leoutsakos et al, 2012). Furthermore, we focus
mainly on Ab whereas the evidence for sTREM2 effects on pathologic tau remains preliminary and may be differentially affected by
microglia activation (Bemiller et al, 2017; Leyns et al, 2017; Jiang
et al, 2018). For findings in the AppNL-G-F and C57BL/6 control
mice, a substantial variability of TSPO expression and rate of
change in Florbetaben PET was observed. However, previous studies demonstrated for both PET tracers a high correlation between
PET uptake and the measurements obtained by the corresponding
immunohistochemical gold standard methods of amyloid deposition
or microglia activity (Rominger et al, 2013; Brendel et al, 2015,
2016; Parhizkar et al, 2019; Sacher et al, 2019). That variability
likely represents a mixture between methodological variability and
interanimal heterogeneity, potentially stemming from interindividual differences in the level of experienced stress (Calcia et al,
2016), physical activity (Kohman et al, 2013), or different stages of
the menstrual cycle (Thakkar et al, 2018). However, these parameters were not assessed in the current study and thus such potential
explanations remain to be confirmed.
Overall, our findings suggest that microglia activation may play a
protective role in the reduction of Ab in AD. These results have
direct therapeutic relevance. Stimulation of microglia activation
such as through TREM2 antibodies is currently being tested in phase
1 trials in AD (https://clinicaltrials.gov/ct2/show/NCT03635047).
The tracking of microglia activity via CSF sTREM2 levels, microglia
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PET, and amyloid PET will play a pivotal role in the evaluation of
the effectiveness of such interventions in AD.

Materials and Methods
Participants
A total of 300 participants were included from the ADNI database.
Beyond the inclusion criteria defined by ADNI, we applied the
following additional selection criteria for the current study: (i) availability of baseline CSF sTREM2 values, (ii) no rare genetic TREM2
variants, (iii) baseline and at least 1 follow-up 18F-Florbetapir
(AV45) amyloid PET assessment, (iv) meeting criteria as cognitively
normal with a negative amyloid PET (Ab ), or (v) showing a positive amyloid PET (i.e., Ab+), regardless of clinical diagnosis. Clinical
classification was performed by ADNI centers as cognitively normal
(CN, MMSE > 24, CDR = 0, non-depressed), mild cognitively
impaired (MCI; MMSE > 24, CDR = 0.5, objective memory-loss on
the education adjusted Wechsler Memory Scale II, preserved activities of daily living) or AD dementia following standard diagnostic
criteria (Petersen et al, 2010). In a subset of 54 participants, AV1451
tau PET was available. Following the recently proposed NIA-AA
guidelines (Jack et al, 2018), we defined evidence of Alzheimer’s
pathologic change by biological markers (i.e., a positive amyloid
PET scan), not by clinical symptoms. CSF sTREM2 measurements at
baseline were assessed via ELISA by the laboratory of C. Haass at
the DZNE Munich as described previously (Suarez-Calvet et al,
2019). The study was ethically approved by the institutional review
boards of all participating ADNI centers. All ADNI participants (or
their relatives) provided written informed consent. All procedures
have been conducted in accordance with the declaration of Helsinki
and the Department of Health and Human Services Belmont Report.
Patient consent
Data were obtained from the multicenter study Alzheimer’s disease
neuroimaging initiative (AD). According to ADNI policy approved
by the centers’ ethics committees, all participants gave their written
consent.
Mouse model
A total of 15 AppNL-G-F mice and 43 age- and gender-matched C57BL/
6 control mice (all female) were assessed with 18F-florbetaben
amyloid PET and 18F-GE180 TSPO-PET as described previously
(Sacher et al, 2019). Breeding of AppNL-G-F mice was performed at the
Center for Neuropathology and Prion Research at LMU Munich.
C57BL/6 mice were purchased from Charles River (Sulzberg,
Germany). Animals were housed in a temperature- and humiditycontrolled environment with a 12-h light–dark cycle, with free access
to food and water. PET imaging sessions were performed longitudinally at 5 and 10 months of age. In brief, amyloid PET was acquired
from 30 to 60 min post-injection and TSPO-PET was acquired from
60 to 90 min post-injection during 1.5% isoflurane anesthesia using a
Siemens Inveon dedicated PET system. PET images of each animal
were spatially co-registered to tracer specific templates and subsequently intensity-normalized using the pre-established periaqueductal
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gray as a pseudo-reference region (Focke et al, 2019). Resulting standardized uptake value ratios (SUVRs) for both ligands were consecutively extracted from a cortical volume of interest. All experiments
were performed in compliance with the National Guidelines for
Animal Protection, Germany, with the approval of the regional
animal committee (Regierung Oberbayern) and were overseen by a
veterinarian. No randomization was used in the current study.
Amyloid PET assessment and computation of annual amyloid
PET change
AV45-PET in ADNI was acquired in a total of six 5-min time-frames
60–90 min after bolus injection of 370 Mbq radiolabeled F18-AV45
tracer. The six time-frames were subsequently co-registered and
averaged to obtain a mean AV45 image. Global AV45 SUVR was
assessed as the mean across selected cortical regions that was intensity-normalized to a composite reference region (including the
whole cerebellum and cerebral white-matter), following a previously described protocol (Landau et al, 2015). The composite reference region was chosen since it has been previously shown to yield
to most stable estimates of longitudinal AV45 changes (Landau
et al, 2015). For each participant, we then determined the annual
changes between subsequently assessed global AV45 SUVR values
(i.e., absolute SUVR difference divided by the time difference in
years). Thus, for participants with more than two AV45 scans, more
than one AV45 change rate was determined (e.g., from baseline to
follow-up 1 and from follow-up 2 to follow-up 3). All AV45 change
rates were subsequently transformed to z-scores with a mean of 0
and a standard deviation of 1.
AV1451 tau PET assessment
Tau PET was assessed 75 min after bolus injection of F18-radiolabeled AV1451 tracer in 6 × 5 min blocks. Recorded images were coregistered and averaged across blocks and intensity-normalized to
the inferior cerebellar gray (Maass et al, 2017). SUVR scores for
Braak-stage-specific ROIs were derived by the ADNI core and downloaded from the ADNI database. Detailed protocols can be found on
the ADNI homepage and in previous publications (Scholl et al,
2016). Note that we excluded Braak-stage 2 (i.e., hippocampus) due
to known off-target binding of the AV1451 tracer in this region
(Lemoine et al, 2018). The cross-sectionally collected AV1451 tau
PET SUVR data (i.e., intensity-normalized to the inferior cerebellar
gray) were acquired maximum 3 years (mean = 1.6 years) after the
sTREM2 assessments and the first available AV45-PET scan.
Statistical analysis
Sample characteristic was compared between study groups using
chi-squared tests for categorical measures and ANOVAS for continuous measures.
To assess whether the baseline AV45 PET shows an u-shaped
association with the rate of AV45 PET accumulation, we computed
linear mixed models with either global AV45 PET or global AV45
PET2 as a predictor of subsequent AV45 PET change, controlling for
age, gender, education, diagnosis, CSF p-tau181, ApoE4 genotype (e4
carrier vs. non-carrier), time between AV45 PET visits, and random
intercept. Note that linear AV45 effects were also included as a fixed
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effect when testing quadratic (i.e., AV45 PET2) effects. Model fit
between the linear (i.e., AV45 PET) and the quadratic (i.e., AV45
PET2) predictors was compared using likelihood ratio tests. Next,
we tested our main hypothesis that higher sTREM2 levels are associated with slower amyloid accumulation. To this end, we used linear
mixed models to test whether global (i) AV45 PET2 and sTREM2
had independent main effects on subsequent AV45 changes, or (ii)
whether there was a global AV45 PET2 × sTREM2 interaction (i.e.,
quadratic) on subsequent AV45 PET changes, controlling for the
linear interaction term (i.e., AV45 × sTREM2) as well as age,
gender, education, diagnosis, CSF p-tau181, ApoE4, time between
AV45 PET visits, and random intercept. In order to test at which
phase of amyloid accumulation, any potential effect of CSF sTREM2
is highest, we performed sliding window analyses on the association
between sTREM2 and future amyloid accumulation at different
levels of baseline AV45 levels. Specifically, we rank-ordered the
subject-wise global amyloid PET-values from low to high and group
subjects into batches of 100 participants at a step size of n = 10,
yielding 62 batches. Within each window (i.e., batch), we then split
the participants between high and low sTREM2 levels (i.e., via
median split, n = 50) and estimated the effect size Cohen’s d for the
difference in the rate of global amyloid PET change between high
and low CSF sTREM2 groups.
To validate the effect of a neuroimmune response on amyloid
accumulation in a preclinical AD model, we tested whether higher
microglial activation (i.e., GE180 PET) was associated with slower
amyloid accumulation (i.e., Florbetaben PET) in the AppNL-G-F
mouse model of AD. Here, we first assessed whether AppNL-G-F AD
mice and C57BL/6 controls had higher Florbetaben and GE180 PET
uptake at 5 months of age using two-sample t-tests. Second, we
tested in the AppNL-G-F AD mice, whether higher baseline GE180 PET
at 5 months of age was associated with slower rate of Florbetaben
PET increase from 5 to 10 months of age, using linear regression
controlling for baseline Florbetaben PET.
In exploratory analyses, we tested whether higher sTREM2 levels
were also associated with lower tau levels. To this end, we included
AV1451 tau PET that was available for an ADNI subsample (n = 54)
within 3 years of the sTREM2 assessments. Using ANCOVAs, we
tested whether higher sTREM2 levels (i.e., defined via median split)
were associated with lower tau PET SUVR in Braak-stage-specific
ROIs, controlling for age, gender, education, diagnosis, ApoE4 as
well as global AV45 amyloid PET and time between the sTREM2
and tau PET assessments. All analyses were performed in R statistical software (Version 3.6.1).
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The paper explained
Problem
Microglia activation forms the brain’s innate immune response to
cerebral pathologies including fibrillar beta-amyloid (Ab), i.e., a
primary pathology in Alzheimer’s disease. TREM2 is a receptor protein
expressed in the brain by microglia, where signaling through TREM2
triggers the phagocytosis of pathogens such as Ab. Since microglia
activation such as that triggered by TREM2 activation constitutes a
potential drug target, understanding the role of increased TREM2 and
microglia activation in AD progression is pivotal. Here, we tested the
role of microglia activation in a two-pronged approach. First, we
assessed cerebrospinal fluid (CSF) biomarker levels of the soluble fraction of TREM2 (sTREM2) as a predictor of longitudinal increase in Ab
as assessed by amyloid PET imaging over 2 years on average in nondemented and demented participants. Second, in order to confirm a
link between higher microglia activation and changes in Ab accumulation, we tested microglia activation (assessed by microglia PET
imaging) as a predictor of rates of amyloid PET increase in a mouse
model of genetically caused Ab.
Results
We found that higher baseline CSF sTREM2 levels were associated
with a slower rate of amyloid PET accumulation, in particular during
phases of intermediate baseline Ab levels in elderly subjects. In the
transgenic mouse model of Ab, we found that higher microglia PET at
5 months of age, i.e., when Ab accumulation starts to emerge globally
in the brain, to be associated with reduced rates of amyloid PET
during a phase until 10 months of age, i.e., a period when Ab is
strongly increasing.
Impact
We conclude that higher microglia activation and in particular TREM2
during a period of intermediate baseline levels of Ab are associated
with reduced rates of Ab accumulation. These results suggest that
enhancing TREM2-related microglia activation may exert protective
effects on Ab.
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